Forensic Analysis · Technology / Software · as of Aug 11, 2026

Omnicell, Inc. (OMCL)

A forensic read on Omnicell, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Safe

Financial health

3.7

Distress distance

Clean

Earnings quality

Forensic signals

43.0

P / E (ttm)

0.2%

ROE

$1.7B

Market cap

6.5%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Omnicell, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 3.7, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

0.3%

FY2025

Return on invested capital. Return on invested capital is 0.3% in the latest fiscal year and steady — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

+16.9%

FY2024→FY2025

Accruals ratio (% of NOA). Net operating assets grew +16.9% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by payables paid down 15% against +6% in cost of sales and inventory up +14% against +6% in cost of sales. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 13% of net operating assets, diverging from the balance-sheet accrual read.

+0.3%/yr

FY2022–FY2025

Share count. Diluted share count changed +1% over the last 3 years to FY2025 (+0.3%/yr). Roughly flat — buybacks ($78M) are about offsetting stock comp ($45M), not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.

Key fundamentals

Latest Revenue$1.18B

Revenue Growth YoY+6.5%

Revenue CAGR (3yr)-2.9%

Net Margin0.2%

Free Cash Flow$86.9M

Return on Equity0.2%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Omnicell, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.